Abstract
β-Adrenergic receptor blockade is a principal treatment for cardiovascular disease, including ischemic heart disease and heart failure (1,2). Hypertension is a leading risk factor for these major causes of death in modern society. Although β-blockers lower blood pressure (BP) in many patients (3,4), their antihypertensive efficacy varies widely among individuals, indicating the pathophysiologic heterogeneity of hypertension (5,6). In fact, of all the hypertensive patients in the United States who are treated with an antihypertensive medication, fewer than half achieve a target pressure of ≤140/90 mmHg (7). This chapter reviews some of the mechanisms by which β-blockers lower BP and provides a rational approach for identifying the hypertensive patient who is most likely to have a favorable response to this treatment.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Gottlieb SS, McCarter RJ, Vogel RA (1998) Effect of beta-blockade on mortality among high-risk and low risk patients after myocardial infarction. N Engl J Med 339: 489–497.
Packer M, Bristow MR, Cohn JN, et al. (1996) The effect of Carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 334: 1349–1355.
Kannel WB (1996) Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA 275: 1571–1576.
Prichard BNC, Cruickshank JM (1995) Beta-blockade in hypertension: past, present, and future. In: Laragh JH, Brenner BM, eds. Hypertension: Pathophysiology, Diagnosis, and Management, vol. 2, New York: Raven, pp. 2827–2859.
Preston RA, Materson BJ, Reda DJ, et al. (1998) Age-race subgroup compared with renin profile as predictors of blood pressure response to antihypertensive therapy. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. JAMA 280: 1168–1172.
Blumenfeld JD, Laragh JH (1998) Renin system analysis: a rational method for the diagnosis and treatment of the individual patient with hypertension. Am J Hypertens 11: 894–896.
Burt VL, Whelton P, Roccella EJ, et al. (1995) Prevalence of hypertension in the U.S. population: results from the Third National Health and Nutrition Examination Survey, 1988–1991. Hypertension 25: 305–314.
McDevitt DG (1981) Differential features of beta-adrenoceptor blocking drugs for therapy. In: Laragh JH, Buhler FR, eds. Selding, D.W., vol. 1, Frontiers in Hypertension Research, New York: Springer-Verlag, pp. 473–481.
Buhler FR. Antihypertensive actions of beta-blockers. In: Laragh JH, Buhler FR, Seldin DW, eds. Frontiers in Hypertension Research, vol. 1, New York: Springer-Verlag, pp. 424–435.
Blumenfeld JD, Vaughan ED Jr (1999) Hypertensive adrenal disorders. In: Brady HR, Wilcox CS, eds. Therapy in Nephrology and Hypertension, vol. 1, Philadelphia: W. B. Saunders, pp. 451–462.
Buhler FR, Laragh JH, Baer L, Vaughan ED Jr, Brunner HR (1972) Propranolol inhibition of renin secretion: a specific approach to diagnosis and treatment of renin-dependent hypertensive diseases. N Engl J Med 287: 1209–1214.
Buhler FR, Laragh JH, Vaughan ED Jr, Brunner HR, Gavras H, Baer L (1973) Antihypertensive action of propranolol: specific antirenin responses in high and normal renin forms of essential, renal, renovascular and malignant hypertension. Am J Cardiol 32: 511–522.
Laragh JH, Sealey JE (1992) Renin-angiotensin-aldosterone system and the renal regulation of sodium, potassium, and blood pressure homeostasis. In: Windhager EE, ed. Handbook of Physiology, Renal Physiology, vol. 2, New York: Oxford University Press, pp. 1409–1541.
Goodfriend TL, Elliott ME, Catt KJ (1996) Angiotensin receptors and their antagonists. N Engl J Med 334: 1649–1654.
Sealey JE, Blumenfeld JD, Bell GM, Pecker MS, Sommers SC, Laragh JH (1988) On the renal basis for essential hypertension: nephron heterogeneity with discordant renin secretion and sodium excretion causing a hypertensive vasoconstriction-volume relationship. J Hypertens 6: 763–777.
Brunner HR, Laragh JH, Baer L, et al. (1972) Essential hypertension: renin and aldosterone, heart attack and stroke. N Engl J Med 286: 441–449.
Laragh JH (1995) Renin system understanding for analysis and treatment of hypertensive patients: a means to quantify the vasoconstrictor elements, diagnose curable renal and adrenal causes, assess risk of cardiovascular morbidity, and find the best fit drug regimen. In: Laragh JH, Brenner BM, eds. Hypertension: Pathophysiology, Diagnosis, and Management, vol. 2, New York: Raven, pp. 1813–1836.
Campbell WG Jr, Gahnem F, Catanzaro DF, et al. (1996) Plasma and renal prorenin/renin, renin mRNA, and blood pressure in Dahl salt-sensitive and salt-resistant rats. Hypertension 27: 1121–1133.
Atlas SA, Sealey JE, Laragh JH, Moon C (1977) Plasma renin and “prorenin” in essential hypertension during sodium depletion, beta-blockade, and reduced arterial pressure. Lancet 2: 785–789.
Blumenfeld JD, Sealey JE, Mann SA, et al. (1999) Beta-adrenergic receptor blockade as a therapeutic approach for suppressing the renin-angiotensin-aldosterone system in normotensive and hypertensive subjects. Am J Hypertens 12: 451–459.
Bragat AC, Blumenfeld J, Sealey JE (1997) Effect of high-performance liquid chromatography on plasma angiotensin II measurements in treated and untreated normotensive and hypertensive patients. J Hypertens 15: 459–465.
Pickering TG, Case DB, Sullivan PA, Laragh JH (1982) Comparison of antihypertensive and hormonal effects of captopril and propranolol at rest and during exercise. Am J Cardiol 49: 1566–1588.
Messerli FH, Grossman E, Goldbourt U (1998) Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. JAMA 279: 1903–1907.
McAlpine HM, Mortin JJ, Leckie B, Rumley A, Gillen G, Dargie HJ (1988) Neuroendocrine activation after acute myocardial infarction. Br Heart J 60: 117–124.
Gavras H, Brown JJ, Lever AF, et al. (1971) Acute renal failure, tubular necrosis, and myocardial infarction induced in the rabbit by intravenous angiotensin II. Lancet 2: 19–22.
Alderman MH, Madhavan S, Ooi WL, Cohen H, Sealey JE, Laragh JH (1991) Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med 324: 1098–1104.
ACE Inhibitor Myocardial Infarction Collaborative Group (1998) Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of the individual data from 100,000 patients in randomized trials. Circulation 97: 2202–2212.
Blumenfeld JD, Sealey JE, Alderman MH, Cohen H, Lappin R, Laragh JH Association between plasma renin activity and acute myocardial infarction in normotensive and hypertensive patients. Am J Hypertens,to be published.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2001 Springer Science+Business Media New York
About this chapter
Cite this chapter
Blumenfeld, J.D. (2001). β-Adrenergic Blocker Treatment of Hypertension. In: Weber, M.A. (eds) Hypertension Medicine. Current Clinical Practice. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-008-7_26
Download citation
DOI: https://doi.org/10.1007/978-1-59259-008-7_26
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-4757-5446-9
Online ISBN: 978-1-59259-008-7
eBook Packages: Springer Book Archive